| [1] |
CHEN Weixin.
Analysis of the immune characteristics of peripheral blood lymphocyte subsets in patients with early and advanced non-small cell lung cancer
[J]. Basic & Clinical Medicine, 2026, 46(6): 823-829.
|
| [2] |
LIU Pengpeng, SUN Zhao, QIU Wei, TANG Hui, ZHU Wenjia, WANG Wenhui, WANG Yingyi.
Impact of local radiotherapy on tyrosine kinase inhibitor treatment in non-small cell lung cancer with oligo-residual disease
[J]. Basic & Clinical Medicine, 2026, 46(4): 491-497.
|
| [3] |
ZHANG Zhen, YANG Lianren, HU Junkun, ZHANG Wei, LIANG Wei.
Value of serum D-dimer in evaluating chemotherapy effect and prognosis in patients with non-small cell lung cancer
[J]. Basic & Clinical Medicine, 2026, 46(3): 417-420.
|
| [4] |
CHEN Xing, LI Yulong, ZHANG Bing, LIANG Jinjie, CHEN Ziyi.
Polyene phosphatidylcholine repairs high glucose-induced human umbilical vein endothelial cells damage
[J]. Basic & Clinical Medicine, 2026, 46(1): 71-77.
|
| [5] |
ZHU Qihai, ZHANG Yu.
The role of hypoxia-inducible factor-1α in the pathogenesis of sarcopenia
[J]. Basic & Clinical Medicine, 2025, 45(8): 1093-1097.
|
| [6] |
LOU Haijun, TONG Zhuoyun, ZHANG Zhenyu, Aheyerk·MAHESHATI, MENG·Menggen, WUDU Muli.
Knockdown of DRAM2 inhibits the proliferation and migration of lung cancer cell line A549
[J]. Basic & Clinical Medicine, 2025, 45(2): 197-202.
|
| [7] |
WANG Luyi, XU Kaifeng.
Factors associated with lymphangioleiomyomatosis progression and mortality
[J]. Basic & Clinical Medicine, 2024, 44(7): 1044-1048.
|
| [8] |
ZHENG Hong, CHEN Xiaoxia, HAN Lizhou, CHEN Miao, HUANGFU Juan.
Decrease of lncRNA-RMRP expression inhibits proliferation and invasion of human lung cancer cell line A549
[J]. Basic & Clinical Medicine, 2024, 44(7): 974-978.
|
| [9] |
CAO Qingwen, QI Lin, YU Bo, TIAN Chenchen, YUAN Haining, WANG Yue.
Salidroside promotes proliferation and migration of human vascular endothelial cell line EA.hy926
[J]. Basic & Clinical Medicine, 2024, 44(7): 925-930.
|
| [10] |
LIANG Xiangcun, WEI Xiaoyu, LIANG Jian, WANG Qing, GENG Guang.
Anlotinib inhibits proliferation and promotes apoptosis of human non-small cell lung cancer cell lines through miR-16-5p/PD-1 axis
[J]. Basic & Clinical Medicine, 2024, 44(4): 503-512.
|
| [11] |
ZHANG Jing, YANG Zigeng, CAI Wenqin, CAO Weiwei, WEI Hongmei, XUE Xixi, WU Bin.
Inhibition of prohibitin 2 enhances the sensitivity of non-small cell lung cancer cell line A549 to erlotinib
[J]. Basic & Clinical Medicine, 2024, 44(3): 325-332.
|
| [12] |
LI Juan, LI Xiaofeng, XU Shengzhi, TANG Kai.
Efficacy of cinobufacini capsule combined with docetaxel plus cisplatin chemotherapy for the treatment of non-small cell lung cancer
[J]. Basic & Clinical Medicine, 2024, 44(2): 247-251.
|
| [13] |
DING Fei, WANG Sa, HUANG Changxin.
Serum CA211 level and NK cell number are associated with prognosis of patients with non-small cell lung cancer
[J]. Basic & Clinical Medicine, 2024, 44(2): 180-184.
|
| [14] |
DU Jingyu, YING Zhanzhuan, HOU Bin, DUO Jie, ZHAO Zhen.
Inhibition of miR-34a reduces inflammatory response in acute exacerbation of chronic obstructive pulmonary disease
[J]. Basic & Clinical Medicine, 2024, 44(12): 1670-1677.
|
| [15] |
.
Association of seven antibody levels in lung cancer with chemotherapy effect and prognosis in patients with NSCLC
[J]. Basic & Clinical Medicine, 2024, 44(10): 1383-1387.
|